Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Intellia Therapeutics, Inc. (NTLA)

Intellia FDA accepts lonvo-z BLA with Priority Review; PDUFA date March 10, 2027

Positive Impact 4 of 5 legal/regulatory Written later

Intellia Therapeutics said the FDA accepted its Biologics License Application for lonvo-z, its investigational one-time treatment for hereditary angioedema, and granted Priority Review with a PDUFA target action date of March 10, 2027. The FDA also said it does not currently plan to hold an advisory committee meeting on the application. The milestone sets a defined regulatory timeline for a product the company says could be the first approved in vivo CRISPR-based therapy.

Key points

  • FDA accepted the BLA for lonvo-z and granted Priority Review
  • PDUFA target action date is March 10, 2027
  • FDA does not currently plan an advisory committee to discuss the application
  • Phase 3 HAELO trial met its primary and all key secondary endpoints, with an 87% reduction in mean monthly attacks versus placebo

The filing

CompanyIntellia Therapeutics, Inc. (NTLA)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:05 PM ET
Accession number0001193125-26-385194

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.